A main concern of mine, is between the first and second crl. Was the clinical utility of the afrezza medication in combination Lantus as compared to the Ancova model which Skhreli claims the FDA demands be the model used in clinical trials proven to be non inferior?


Also, other than comparing the efficacy of dreamboat vs medtone, what other issues does mannkind face in regards to proving non-inferiority, and efficacy/clinical utility of afrezza when comparing to the Ancova model?? Would these issues be asserted in the current trials if they have not already?